Healthcare
8×8 (EGHT) Upgrade from Market Perform to Outperform – Analyst rating from Northland Securities
Tuesday, August 9th, 20118×8 ( EGHT ) Upgrade from Market Perform to Outperform – Analyst rating from Northland Securities
Tuesday, August 9th, 2011RDY – Dr. Reddys Announces the Launch of Gemcitabine for Injection
Wednesday, July 27th, 2011Dr. Reddy’s Q1 FY12 Financial Results
Wednesday, July 20th, 2011Key Highlights Consolidated revenues are at Rs. 19.7 billion ($444 million) in Q1 FY12 versus Rs. 16.8 billion ($377 million) in Q1 FY11, year-on-year growth of 18%. Revenues from Global Generics for Q1 FY12 are at Rs. 14.4 billion ($323 million). Year-on-year growth of 21% mainly driven by North America generics and Russia. Revenues from [...]
Dr. Reddy’s Laboratories
Wednesday, June 1st, 2011Dr. Reddy’s Laboratories is an integrated pharmaceutical company and operates in business segments such as global generics, active ingredients and proprietary products. Dr Reddy’s March quarter results were higher-than-estimated with revenue growing 22.8% year-over-year, driven by robust growth of 67.6% in U.S. generics and 25.7% in Russia and CIS. The launch of generic fexofenadine pseudoephedrine [...]
Dr Reddy’s says U.S. court clears generic Allegra sale
Wednesday, February 2nd, 2011“This is a positive for the company. Since Dr Reddy’s is the only player for this product, it should be able to do decent sales,” Sarabjit Kour Nangra, vice president of research and who tracks the sector at Angel Broking said. Dr. Reddy’s Laboratories announced today that on Friday, 28 January 2011, the U.S. District [...]
Dr Reddy’s Laboratories will start to see the benefits from its tie-up with GlaxoSmithKline in two or three years
Wednesday, February 2nd, 2011“Overall, it is a good relationship that is working well and going as predicted, but the financial impact is going to be seen only two to three years from now,” he told Reuters on the sidelines of the annual meeting of the World Economic Forum. “It takes time to develop the products and register them [...]
8×8 (EGHT) Downgrade from Outperform to Market Perform – Analyst rating from Northland Securities
Thursday, January 27th, 20118×8 ( EGHT ) Downgrade from Outperform to Market Perform – Analyst rating from Northland Securities
Thursday, January 27th, 2011Dr. Reddy’s Laboratories Ltd. (RDY) Q3 2011 Earnings Call
Wednesday, January 26th, 2011The financial highlights are as follows. Consolidated revenues for the quarter are at $424 million and represent a year-on-year growth of 10% and a sequential growth of 2%. Revenues from our Global Generics business stand at $303 million for the quarter, representing a year-on-year growth of 16%. Revenues from the Pharmaceutical Services and Active Ingredients [...]
Dr Reddy’s profit hurt by German unit, shares fall
Wednesday, January 26th, 2011Dr Reddy’s Laboratories, India’s No. 2 drugmaker, swung to a profit in the third quarter but missed analysts’ estimates as sales at its German unit plunged. Sales in Europe, one of Dr Reddy’s largest markets, fell 18 percent, driven by a 33-percent drop in Germany, as its German unit Betapharm struggled with pricing pressure amid [...]
Biosimilars – The Next Generic Honeypot
Tuesday, September 14th, 2010Generic drugs are certainly a significant part of the landscape in the healthcare world. Not only do they save healthcare consumers (and their insurance companies) millions of dollars a year, but they are a thriving industry in their own right. Companies like India’s Dr. Reddy’s Laboratories (NYSE:RDY) and its nearly ten-fold larger rival Teva Pharmaceuticals [...]
8×8 (EGHT) Initial Recommendation – Outperform – Analyst rating from Northland Securities
Monday, March 22nd, 20108×8 ( EGHT ) Initial Recommendation Outperform – Analyst rating from Northland Securities
Monday, March 22nd, 2010Dr Reddy’s forecasts low single digit revenue growth in FY10
Wednesday, January 20th, 2010Chief Executive G.V. Prasad said the company expected to post a “low single digit” revenue growth in the fiscal year that ends in March, down from its previous forecast of a 10-percent growth over the previous year. “Our German business has contracted beyond our expectations and there is a little bit of slowdown in the [...]
Dr Reddy’s posts $113 mln net loss in Q3
Wednesday, January 20th, 2010Indian drug maker Dr Reddy’s Laboratories Ltd posted a 5.2 billion rupees consolidated loss ($113 million) in the December quarter, compared with a profit of 2.4 billion rupees in the year-ago period, missing forecasts. Dr Reddy’s, India’s second-biggest drug maker by sales, said in September it had voluntarily recalled four products from its key U.S. [...]
Dr. Reddy’s (RDY) Downgrade from Hold to Sell – Analyst rating from Deutsche Bank
Tuesday, January 19th, 2010Dr. Reddy’s downgraded by Deutsche Bank
Tuesday, January 19th, 2010Transgene Biotek Sells Obesity Drug Technology License To Dr Reddy’s
Thursday, January 7th, 2010Transgene Biotek Ltd. said Thursday it has sold the license for the manufacturing process of obesity drug orlistat to Dr. Reddy’s Laboratories Ltd.
Analyst rating from Credit Suisse – Upgrade Dr. Reddy’s ( RDY ) from Neutral to Outperform
Monday, October 26th, 2009Merck startet Phase-III-Studie mit Safinamid
Wednesday, November 28th, 2007Merck Serono, eine Sparte der Merck KGaA, und ihr Partner Newron Pharmaceuticals S.p.A. haben eine klinische Phase-III-Studie mit Safinamid gestartet. Wie der im DAX30 notierte Pharmakonzern am Mittwoch erklärte, wird Safinamid dabei als Begleittherapie bei idiopathischer Parkinson-Erkrankung im Frühstadium getestet. Die Studie wird die Sicherheit und Wirksamkeit von zwei Dosierungen von Safinamid (50 mg und [...]
Human Genome Sciences outperform
Wednesday, September 19th, 2007Sanford C. Bernstein & Co stufen die Aktie von Human Genome Sciences in ihrer Ersteinschätzung mit “outperform” ein. Das Kursziel wird bei 13 US-Dollar gesehen.
Human Genome erhält Meilensteinzahlung von Novartis
Friday, September 7th, 2007Human Genome Sciences Inc. wird vom schweizerischen Pharmakonzern Novartis AG eine Meilensteinzahlung in zweistelliger Millionenhöhe erhalten.
Neue Spekulationen um Bayer und Novartis
Wednesday, August 22nd, 2007Um Bayer AG ranken sich Übernahmespekulationen. Am Parkett wird darauf spekuliert, der Schweizer Pharmariese Novartis AG , der weltweit sechstgrößte Pharmakonzern und die Nummer vier in Europa, könnte ein Angebot für das Leverkusener Unternehmen vorlegen.
Human Genome verringert Verlust im zweiten Quartal
Wednesday, August 1st, 2007Human Genome Sciences Inc. konnte den Verlust im zweiten Quartal deutlich reduzieren.Wie der Konzern am Mittwoch erklärte,
weekly winner – ENCY + 21,3%
Sunday, July 22nd, 2007Genentech posts 41% rise in profit, lifts full-year EPS view
Wednesday, July 11th, 2007Genentech Inc. after Wednesday’s closing bell said it made $747 million, or 70 cents a share, in the second quarter, compared with $531 million, or 49 cents a share, in the same quarter last year.
Human Genome Sciences – Downgrade
Tuesday, June 26th, 2007Lehman Brothers — 26.06.07 —- HGSI — downgrade von overweight auf equal weight — Kursziel gesenkt von 15 $ auf 10 $
Monsanto schliesst mit Bayer langfristige Vereinbarung
Thursday, June 21st, 2007Monsanto schliesst mit Bayer CropScience langfristige Geschäfts- und Lizenzvereinbarung.
BASF overweight
Wednesday, June 20th, 200718.06.07 – Morgan Stanley – BASF overweight – price target 100 USD
Mylan Laboratories übernimmt Generikageschäft von Merck
Thursday, May 17th, 2007Mylan wird man das Generikageschäft des deutschen Pharmakonzerns Merck für 4,9 Mrd. Euro übernehmen. Die Transaktion soll im zweiten Halbjahr 2007 abgeschlossen werden